Vous êtes redirigé vers un site externe.

GSK n'accepte aucune responsabilité suite à l'utilisation des sites internet tiers, y compris en ce qui concerne leur contenu.

Poursuivre

Retour

ANORO® 55/22mcg

What is Nucala?

Nucala is indicated as an add-on treatment for adult, adolescent and paediatric patients (aged 6 or above) with severe refractory eosinophilic asthma. 1 Nucala is administered as a subcutaneous injection at a fixed dose once every four weeks. 1

How does Nucala work?

Go to Close Top

Nucala targets IL-5, the main cytokine responsible for the growth and differentiation, recruitment, activation, and survival of eosinophils. By inhibiting IL-5 signalling, Nucala reduces the production and survival of eosinophils. 13

Video player requires JavaScript enabled. You can download this video here: https://videos.gskstatic.com/pharma/GSKpro/Belgium/mp4/nucala_mode_of_action_video.mp4

Who could benefit from Nucala?

*Fictional patient for discussion only.

Patients who are likely to benefit from Nucala should have two or more controller therapies, including high-dose ICS and additional controller(s) and two or more exacerbations in the previous 12 months and/or daily OCS. 1

Nucala is recommended for long-term treatment and its use should be reviewed on an annual basis. 1

Clinical response to Nucala is predicted in patients with eosinophil counts ≥150 cells/μL at initiation of treatment or ≥300 cells/μL in the prior 12 months. 6

Guide pratique

Introduction à Nucala, ....

BE/NLA/0016/17b(1) 

Item added

Nucala (Mepolizumab)

Brochure d'information pour les patients

BE/NLA/0013/16(2)

Item added

Guide pratique

Introduction à Nucala, ....

BE/NLA/0016/17b(1) 

Item added

Abbreviations:

IL-5, interleukin-5.

References:

  1. Nucala SmPC.
  2. Wen T, Rothenberg ME. Microbiol Spectr 2016; doi: 10.1128/microbolspec.MCHD-0020-2015.
  3. Weller PF, Spencer LA. Nat Rev Immunol 2017; 17:746–760.
  4. Price D et al. J Asthma Allergy 2016; 9:1–12.
  5. Garcia G et al. Eur Respir Rev 2013; 22:251–257.
  6. Ortega HG et al. Lancet Respir Med 2016; 4:549–556.

Nucala - Respiratoire
(Mepolizumab)

Indication:
Nucala est indiqué chez l'adulte, en traitement additionnel, dans l’asthme sévère réfractaire à éosinophiles.

Nucala est une marque déposée de GlaxoSmithKline.

© 2019 GSK Group of Companies or its licensor. Trademarks are the property of their respective owners

Nucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older. 1

Only Nucala 100mg SC is licensed in patients aged 12 years and older.

Only Nucala 40mg SC is licensed in patients aged 6–11 years.

Mepolizumab IV is not a licensed dose of administration